Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
MDC M.D.C.	$62.95 0.0%	$62.68	$36.47 ▼ $63.00	$4.72B	1.54	1.91 million shs	2.14 million shs
OCX OncoCyte	$2.59 -5.8%	$2.95	$2.08 ▼ $6.80	$21.39M	0.8	48,471 shs	35,975 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
MDC M.D.C.	+0.10%	+0.10%	+0.54%	+18.59%	+64.34%
OCX OncoCyte	+8.70%	-4.51%	-7.72%	-19.12%	-55.37%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDC M.D.C.	1.8057 of 5 stars	0.9	4.0	1.7	0.0	2.6	4.2	1.3
OCX OncoCyte	1.7349 of 5 stars	3.3	1.0	0.0	0.0	2.9	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A
MDC M.D.C.	1.80	Reduce	$52.13	-17.20% Downside
OCX OncoCyte	2.67	Moderate Buy	$3.90	50.58% Upside

Current Analyst Ratings

Latest OCX, FRX, and MDC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2024	OCX OncoCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$4.00
4/15/2024	OCX OncoCyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$5.00
2/7/2024	MDC M.D.C.	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
1/31/2024	MDC M.D.C.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$57.00 ➝ $63.00

(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
MDC M.D.C.	$4.64B	1.02	$5.32 per share	11.83	$45.24 per share	1.39
OCX OncoCyte	$1.50M	14.26	$0.92 per share	2.83	$5.78 per share	0.45

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MDC M.D.C.	$401.01M	$5.28	11.92	∞	N/A	8.64%	12.32%	7.34%	5/7/2024 (Estimated)
OCX OncoCyte	-$27.78M	N/A	0.00	∞	N/A	-3,923.58%	-77.26%	-33.66%	5/9/2024 (Estimated)

Latest OCX, FRX, and MDC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
1/30/2024	12/31/2023	MDC M.D.C.	$1.50	$1.56	+$0.06	$1.56	$1.29 billion	$1.31 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
MDC M.D.C.	$2.20	3.49%	+17.73%	41.67%	1 Years
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A

Latest OCX, FRX, and MDC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/17/2024	MDC M.D.C.	quarterly	$0.55	3.5%	2/6/2024	2/7/2024	2/21/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRX Forest Road Acquisition	N/A	0.37	0.37
MDC M.D.C.	0.50	9.76	3.92
OCX OncoCyte	N/A	2.11	2.11

Ownership

Institutional Ownership

Company	Institutional Ownership
FRX Forest Road Acquisition	N/A
MDC M.D.C.	88.08%
OCX OncoCyte	55.35%

Insider Ownership

Company	Insider Ownership
FRX Forest Road Acquisition	N/A
MDC M.D.C.	23.30%
OCX OncoCyte	1.94%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
MDC M.D.C.	1,760	75.05 million	57.56 million	Optionable
OCX OncoCyte	75	8.26 million	8.10 million	No Data

OCX, FRX, and MDC Headlines

Source	Headline
	OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 Shares americanbankingnews.com - April 16 at 6:58 AM
	OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of Stock americanbankingnews.com - April 16 at 5:44 AM
	OncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at Benchmark americanbankingnews.com - April 16 at 4:50 AM
	OncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stock insidertrades.com - April 16 at 4:46 AM
	OncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of Stock americanbankingnews.com - April 16 at 4:18 AM
	OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript seekingalpha.com - April 13 at 10:47 PM
	Q4 2023 OncoCyte Corp Earnings Call finance.yahoo.com - April 13 at 1:38 AM
	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 investorplace.com - April 12 at 12:00 PM
	Top 3 Health Care Stocks That May Collapse In Q2 msn.com - April 12 at 10:36 AM
	OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay finanznachrichten.de - April 12 at 10:10 AM
	S&P Futures Tick Lower as Investors Digest Big Bank Earnings msn.com - April 12 at 10:10 AM
	S&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earnings msn.com - April 12 at 7:32 AM
	Oncocyte announces $15.8 mln private placement of securities msn.com - April 12 at 7:32 AM
	ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS prismmediawire.com - April 12 at 6:00 AM
	Oncocyte Reports Full Year 2023 Financial Results globenewswire.com - April 12 at 6:00 AM
	OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com americanbankingnews.com - April 12 at 2:16 AM
	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules prismmediawire.com - April 11 at 9:48 PM
	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules globenewswire.com - April 11 at 9:46 PM
	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay globenewswire.com - April 11 at 5:30 PM
	Here's what Wall Street expects from Oncocyte's earnings markets.businessinsider.com - April 11 at 12:51 PM
	ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS  prismmediawire.com - April 9 at 4:05 PM
	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results globenewswire.com - April 9 at 4:05 PM
	NeuroBo stock jumps 14% on weight-loss drug update msn.com - February 29 at 10:17 AM
	OncoCyte Stock (NASDAQ:OCX), Short Interest Report benzinga.com - February 24 at 8:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Forest Road Acquisition

NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

M.D.C.

NYSE:MDC

M.D.C. Holdings, Inc., through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company conducts its homebuilding operations in Arizona, California, Nevada, New Mexico, Oregon, Texas, Washington, Colorado, Idaho, Utah, Alabama, Florida, Maryland, Pennsylvania, Tennessee, and Virginia. Its financial services operations comprise originating mortgage loans primarily for homebuyers; providing insurance coverage primarily to its homebuilding subsidiaries and subcontractors for homes sold by its homebuilding subsidiaries, and for work performed in completed subdivisions; acting as a re-insurer on the claims; selling third-party personal property and casualty insurance products to homebuyers; and offering title agency services to homebuilding subsidiaries and customers in Colorado, Florida, Maryland, Nevada, Pennsylvania, and Virginia. The company was founded in 1972 and is headquartered in Denver, Colorado.

OncoCyte

NASDAQ:OCX

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial